Advertisement

Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies

      Objective

      To assess the efficacy and safety of tadalafil, a phosphodiesterase 5 (PDE5) inhibitor efficacious for erectile dysfunction and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), in population subgroups, using pooled data from 4 international, randomized, placebo-controlled studies in men with LUTS/BPH.

      Methods

      The safety database included 1500 men randomized to tadalafil 5 mg once daily or placebo for 12 weeks. Changes in total International Prostate Symptom Score (IPSS), IPSS-quality of life index, and BPH impact index were examined overall, and changes in IPSS or adverse events (AEs) were examined across subgroups of interest. Treatment-group differences were assessed using analysis of covariance.

      Results

      Results of pooled data confirmed that tadalafil (N = 752) resulted in significant improvements from baseline vs placebo (N = 746) in IPSS (mean difference −2.3; P <.001), and also in BPH impact index and IPSS-quality of life index (both P <.001). Subgroup analyses demonstrated that IPSS improvements were significant regardless of baseline LUTS severity (IPSS <20/≥20), age (≤65/>65 years), recent previous use of α-blockers or PDE5 inhibitors, total testosterone level (<300/≥300 ng/dL), or prostate-specific antigen predicted prostate volume (≤40/>40 mL). Rates of treatment emergent AEs were comparable between subgroups of baseline age (≤65/>65 years), previous PDE5 inhibitor use, and the presence or absence of pre-existing diabetes, hypertension, or cardiovascular disease (including hypertension), but somewhat higher for recent previous α-blocker use.

      Conclusion

      In these pooled data analyses, tadalafil 5 mg improved LUTS/BPH across subgroups of age, LUTS severity, testosterone levels, and prostate volume. Rates of AEs were similar across the subgroups assessed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boyle P.
        • Robertson C.
        • Mazzetta C.
        • et al.
        The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study.
        BJU Int. 2003; 92: 719-725
        • Irwin D.E.
        • Milsom I.
        • Hunskaar S.
        • et al.
        Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.
        Eur Urol. 2006; 50: 1306-1314
        • McVary K.T.
        BPH: epidemiology and comorbidities.
        Am J Manag Care. 2006; 12: S122-S128
        • Verhamme K.M.
        • Dieleman J.P.
        • Bleumink G.S.
        • et al.
        Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the Triumph project.
        Eur Urol. 2002; 42: 323-328
        • Coyne K.S.
        • Kaplan S.A.
        • Chapple C.R.
        • et al.
        Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS.
        BJU Int. 2009; 103: 24-32
        • Kaplan S.A.
        • Roehrborn C.G.
        • Chapple C.R.
        • et al.
        Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms.
        BJU Int. 2009; 103: 48-57
        • Kupelian V.
        • McVary K.T.
        • Kaplan S.A.
        • et al.
        Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey.
        J Urol. 2009; 182: 616-624
        • Rosen R.
        • Altwein J.
        • Boyle P.
        • et al.
        Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).
        Eur Urol. 2003; 44: 637-649
        • Oelke M.
        • Giuliano F.
        • Mirone V.
        • et al.
        Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
        Eur Urol. 2012; 61: 917-925
        • Porst H.
        • Kim E.D.
        • Casabe A.R.
        • et al.
        Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
        Eur Urol. 2011; 60: 1105-1113
        • Roehrborn C.G.
        • McVary K.T.
        • Elion-Mboussa A.
        • et al.
        Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
        J Urol. 2008; 180: 1228-1234
        • Egerdie R.B.
        • Auerbach S.
        • Roehrborn C.G.
        • et al.
        Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
        J Sex Med. 2012; 9: 271-281
        • Barry M.J.
        • Fowler Jr., F.J.
        • O'Leary M.P.
        • et al.
        The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.
        J Urol. 1992; 148: 1549-1557
        • Barry M.J.
        • Fowler Jr., F.J.
        • O'Leary M.P.
        • et al.
        Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association.
        Med Care. 1995; 33: AS145-AS155
        • Roehrborn C.G.
        The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
        Int J Impot Res. 2008; 20: S19-S26
        • Porst H.
        • Hell-Momeni K.
        • Buttner H.
        Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
        Expert Opin Pharmacother. 2012; 13: 1481-1494
        • Porst H.
        • Roehrborn C.G.
        • Secrest R.J.
        • et al.
        Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from 4 randomized, placebo-controlled tadalafil clinical studies.
        J Sex Med. 2013; (Accepted)

      Linked Article

      • Erratum
        UrologyVol. 83Issue 3
        • Preview
          The authors of “Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies” by Porst H., Oelke M., Goldfischer E.R., Cox D., Watts S., Dey D., et al (Urology 2013;82:667-673) have identified errors mainly related to incorrect cutoff values for predicted prostate volume as outlined below. These errors do not change the interpretation of the data.
        • Full-Text
        • PDF